Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA‐SWITCH): a randomized, double‐blind, double‐dummy, active‐controlled 26‐week trial

AIMS: To confirm superiority on glycaemic control by switching from sitagliptin to liraglutide 1.8 mg/d versus continued sitagliptin. MATERIALS AND METHODS: A randomized, multicentre, double‐blind, double‐dummy, active‐controlled trial across 86 office‐ or hospital‐based sites in North America, Euro...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, T. S., Takács, R., Tinahones, F. J., Rao, P. V., Tsoukas, G. M., Thomsen, A. B., Kaltoft, M. S., Maislos, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129465/
https://www.ncbi.nlm.nih.gov/pubmed/27381275
http://dx.doi.org/10.1111/dom.12736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129465/
https://www.ncbi.nlm.nih.gov/pubmed/27381275
http://dx.doi.org/10.1111/dom.12736

Ejemplares similares